The recommendation from the National Institute for Clinical Excellence (NICE) that zanamivir (Relenza) should not be prescribed for in¯uenza was a bold step for ā edgling organization. The way in which this decision was taken avoided the turmoil that followed the Government's earlier ruling on sildena®l (Viagra).
In most people, in¯uenza lasts 2±7 days. Secondary complications are rare, but groups at special risk include the elderly and patients with underlying morbidity such as coronary vascular disease, asthma, chronic obstructive pulmonary disease and immunosuppression. In the UK vaccination is recommended for people over the age of 75 and for people considered to be at high-risk, but the present uptake is only 40%.
Zanamivir (Relenza) is licensed in the UK as a prescription-only medication for the treatment of in¯uenza A and B in adults and adolescents. It is a new class of antiviral agent that selectively inhibits in¯uenza A and B virus neuraminidases. In trials in adults with in¯uenza A or B virus infections, direct administration of zanamivir to the respiratory tract reduced the length of clinically important symptoms by 1 day 1 . In`high-risk' patients it reduced the duration of symptoms by 2.5 days (95% con®dence interval 71.0 to 8.0, P=0.048) 2 ; however, the sample size of this latter group was small (76 patients) and most of the patients classi®ed as high-risk had only mild asthma.
The purposes of NICE are to bring effective medicine to the market more quickly, to end`post-code rationing', to ensure that taxpayers get value for money and to provide a rational basis for NHS decision-making. The then Health Secretary, Frank Dobson requested NICE to advise the Government on the prescribing of zanamivir on the NHS. At the beginning of October the Rapid Appraisal Committee of NICE recommended that zanamivir should not be prescribed to patients during the 1999/2000 in¯uenza season, making clear that this guidance was intended to assist health professionals in their decisionmaking and that they should continue to exercise their clinical judgment in determining appropriate treatment for patients with symptoms of in¯uenza 3 . In the opinion of NICE, there was insuf®cient evidence of its effectiveness in reducing the frequency of serious complications. Frank Dobson backed this advice and zanamivir was not blacklisted' by the Government.
The Relenza ruling differs from that taken in 1998 for sildena®l (Viagra), in that the Government unof®cially banned Viagra before permission was granted, some months later, for health professionals to prescribe it for speci®c conditions. The Viagra ruling restricts prescribing of Viagra on Schedule 11 of the NHS (GMS) regulations 1992 and in so doing rations this treatment. Other differences exist between the Viagra and Relenza cases; Viagra is a highly effective treatment for a very prevalent condition, for which there is a large unmet need with the potential to absorb huge amounts of NHS fundingÐbut impotence is not life threatening.
What are the implications of the Relenza ruling? The implications for NICE itself are that it has established itself in the public consciousness, it has demonstrated the future impact it may have on the operation of the NHS and it has shown itself able to make strong decisions against a large British pharmaceutical company. In response, Glaxo Wellcome has requested a re-evaluation of the NICE decision-making process and has threatened to move its investment overseas; more importantly, the ruling has ensured that new clinical trials will be conducted quickly in time to inform the review of Relenza for next year's in¯uenza season. For the NHS and general practitioners the ruling will prevent overuse of already stretched resources, while allowing GPs to continue exercising their own clinical judgment. In summary, NICE has made a good start.
